Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Investment

Moderna picks Kenya for African mRNA facility

by Michael McCoy
March 19, 2022 | A version of this story appeared in Volume 100, Issue 10

Moderna says it will build a messenger RNA (mRNA) therapeutics plant in Kenya at a cost of up to $500 million. The facility will make mRNA active ingredients and could be expanded to produce finished therapies such as Moderna’s COVID-19 vaccine. The firm’s announcement advances a promise it made in October 2021 to build an mRNA facility somewhere in Africa. Last month, BioNTech, which with Pfizer produces another mRNA COVID-19 vaccine, said it would establish modular production systems in Africa.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.